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ABSTRACT
Purpose: Survival outcomes in patients presenting with well-differentiated thyroid cancer with pulmonary
metastasis are variable. The aim of this study was to evaluate prognostic factors for outcome in this pa-
tient population. Methods: A prospective registry database was searched to identify patients presenting
with pulmonary metastasis from well-differentiated thyroid cancer. All patients underwent total thy-
roidectomy and postoperative I-131 therapy. Cox proportional hazards modeling was performed to eval-
uate prognostic factors for survival outcomes. Results: Forty (40) patients were identified with well-dif-
ferentiated thyroid cancer involving the thyroid and metastatic to cervical lymph nodes and lung at initial
diagnosis. The median follow-up was 9.7 years for those alive at last follow-up. Cox proportional haz-
ards modeling evaluated age at diagnosis, gender, primary tumor size, and vascular invasion on cause-
specific and progression-free survivals. Age at diagnosis was the only significant independent prognos-
tic factor (p  0.0035). The 10-year cause-specific survivals were 100% in patient’s 40 years, compared
to 36% for those 40 years (p  0.0001). The corresponding 10-year progression-free survivals were
69% and 12% (p  0.0003). Conclusions: Patients 40 years of age presenting with pulmonary metas-
tasis from well-differentiated thyroid cancer had an excellent prognosis. Older patients have a poor sur-
vival outcome. Postoperative I-131 therapy is recommended in all patients.
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INTRODUCTION
Well-differentiated thyroid carcinoma affects
both children and adults and is accompanied by
distant metastasis at the time of diagnosis in a mi-
nority of cases.1–10 Pulmonary metastases is the
most common at diagnosis and is detected in
3%–20% of patients.11–15 Pulmonary metastasis
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is more common in children and young adults9
and is associated with excellent survival after ini-
tial treatment or recurrence.16–18 Poor long-term
survival has been reported for older patients 
with metastatic well-differentiated thyroid can-
cer,8,10,14,15,19,20 but age has not been shown to
be an independent predictor of survival in other
reports.1,6 This analysis was performed to study
the impact of prognostic factors at diagnosis on
progression-free and cause-specific survivals in
patients presenting with well-differentiated thy-
roid cancer and pulmonary metastasis.
MATERIALS AND METHODS
A prospective registry of patients with thyroid
cancer referred to the Mallinckrodt Institute of
Radiology (MIR; Washington University School
of Medicine, St. Louis, MO) from 1970 to 2006
was searched to identify patients with pulmonary
metastasis at time of diagnosis. Approval from
the Institutional Review Board (Washington Uni-
versity Human Research Protection Office) was
obtained for this study. The registry included
1333 patients with newly diagnosed, well-differ-
entiated papillary thyroid carcinoma. None of the
patients had follicular carcinoma. Of these, 40 pa-
tients (3%) were identified with pulmonary me-
tastasis detected on 131I scintigraphy at the time
of the initial thyroid cancer diagnosis and treat-
ment. The size of the pulmonary metastases could
not be determined, since the information was not
recorded in the clinical records for all patients.
None of these patients were known to have a his-
tory of prior radiation exposure.
All patients underwent a total thyroidectomy and
received postoperative 131I therapy, according to
standard institutional practice. For adults, the gen-
eral guideline was to administer 150–250 mCi of
131I (5.55–967.25 GBq), and children usually re-
ceived the corresponding dosage adjusted for body
weight (3.57 mCi/kg, 0.13GBq/kg)). Whole-body
131I scintigraphy was performed 2–5 days after
treatment. Repeat 131I administration was per-
formed for residual or recurrent disease. Patients re-
ceived a mean 131I-administered activity of 448 mCi
(16.6 GBq) (maximum, 1400 mCi, 51.8 GBq). The
presence of pulmonary metastasis and response to
treatment were detected by whole-body scintigra-
phy with 131I. Persistent and recurrence disease sites
were detected by clinical examination, thyroglobu-
lin assay, or I-131 scintigraphy. Follow-up I-131
scintigraphy was performed with 5 mCi I-131.
Cause-specific survival is defined as death re-
sulting from thyroid cancer. Progression-free sur-
vival is defined as the development of recurrent
thyroid cancer. Cause-specific survival and pro-
gression-free survival were estimated by using
the Kaplan-Meier method.21 The equivalence of
the survival estimates was evaluated by using the
Mantel-Cox statistic.22 Multivariate analysis was




The patient population consisted of 24 males and
16 females. Their median age was 38 years (range,
4–83). The tumor histologic type was well-dif-
ferentiated thyroid cancer in all patients. None of
the patients had poorly differentiated or anaplas-
tic carcinoma. The mean and median follow-up
times for all patients alive at the time of last fol-
low-up were 12.3 and 9.7 years (range, 2–37).
Prognostic Factors
All patients in this study were known to have me-
tastasis to cervical lymph nodes and lung at the
time of diagnosis. Other established prognostic
factors were evaluated by Cox multivariate pro-
portional hazards modeling. These factors in-
cluded age at diagnosis, gender, primary tumor
size, local soft-tissue invasion, and vascular in-
vasion. Patient age was the only significant in-
dependent predictor of progression-free survival
(p  0.0061) and of cause-specific survival (p 
656
Figure 1. Cause-specific survival by age at time of diag-
nosis.
0.0035). Neither gender (p  0.12), primary tu-
mor size (p  0.15), local soft tissue invasion
(p  0.19), nor vascular invasion by tumor (p 
0.26) were independent predictors of cause-spe-
cific survival in this model.
Because age at diagnosis was the only inde-
pendent prognostic factor, its effect was further
evaluated. The log-rank (Mantel-Cox) statistic
was used to determine the cut-off age value that
was strongly predictive of prognosis. It was found
that patients 40 years had a significantly better
outcome than those 40 years (Figs. 1 and 2).
The 10-year cause-specific survivals were 100%
in patients 40 years, compared to 36% for those
40 years (p  0.0001). The corresponding 10-
year progression-free survivals were 69% and
12%, respectively (p  0.0003).
Recurrence
Nineteen (19) of 40 patients had persistent lung
metastasis or developed new sites of recurrence
after 131I therapy. Recurrence sites are shown in
Table 1. Persistent metastatic disease in the lung
was the most common site of disease (13/19).
Twenty-one (21) patients became disease free.
DISCUSSION
The prognosis of patients presenting with pul-
monary metastasis from well-differentiated thy-
roid cancer is variable after standard therapy. In
the current study, cause-specific survivals were
100% for patients 40 years of age and younger
and 36% in patients older than 40 years. Young
age has been reported to be a positive predictor
of prolonged survival.2,8,10,14,15,19,20,24 On the
other hand, some recent reports have not found
age to be a significant independent factor.1,6 Most
investigators report young age as a predictor of
survival but fail to address the issue of what is
the cut-off age for a poor prognosis. Our data
demonstrate no cancer-related deaths for patients
less than 40 years, whereas most patients older
than 40 years will die from metastatic thyroid
cancer.
Thyroid cancer has a favorable overall prog-
nosis in children and young adults, despite a pat-
tern of disseminated disease and frequent recur-
rence.16–18,25 Cervical lymphadenopathy and
distant metastasis are more common in children
and adolescents than in adults. The inconsistency
between extensive disease at presentation and
positive outcome after therapy is characteristic of
childhood well-differentiated thyroid cancer, but
the reason for this apparently discordant behav-
ior has not been described.25
Excellent outcome after aggressive treatment
with thyroidectomy and 131I administration for
young patients with metastatic well-differenti-
ated thyroid cancer supports the use of 131I ther-
apy in these patients. The positive survival re-
sults in younger patients may be explained by
less aggressive tumor biology, but 131I therapy
is recommended, based upon excellent survival
rates achieved in patients with metastasis.25,26
For older patients with pulmonary metastasis
from well-differentiated thyroid cancer, survival
may be improved through a similar approach,
using 131I administration until complete remis-
sion of disease, with multiple treatments to high
cumulative activities.19,27 A treatment protocol
that includes total thyroidectomy and postoper-
ative 131I therapy reduces the rate of recurrence
and allows for the early detection of pulmonary
metastasis.28,29
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Figure 2. Progression-free survival by age at time of di-
agnosis.
Table 1. Recurrence Sites
Recurrence site Number of patients
Cervical LN 3
Lung 6
Cervical LN  lung 4




Uptake of 131I by pulmonary metastases from
well-differentiated thyroid cancer has been shown
to be an important factor associated with pro-
longed survival time.19,26 This observation un-
derscores the important role of 131I therapy in the
successful treatment of disseminated well-differ-
entiated thyroid cancer. 131I therapy decreases the
tumor burden in patients with pulmonary metas-
tasis from well-differentiated thyroid cancer30 and
should be administered to patients whose tumors
concentrate 131I. Three-dimensional lung and
bone marrow dosimetry may be performed for pa-
tients with 131I-avid pulmonary metastases from
well-differentiated thyroid cancer.31,32 Use of
large cumulative activities has been reported with
minimal clinical toxicity.29,33 For older patients
with metastatic well-differentiated thyroid cancer,
the incorporation of systemic agents into thera-
peutic regimens may be a promising avenue for
future research, given the availability of molecu-
larly targeted drugs27 and because of the subopti-
mal outcomes after standard treatment. Definitive
proof of benefit of I-131 therapy for I-131-avid
lung metastases is lacking because there is no
group of “control” or untreated patients.
CONCLUSIONS
In the current study of patients presenting with
pulmonary metastasis from well-differentiated
thyroid cancer, no deaths were observed in patients
40 years of age or younger, whereas pulmonary
metastasis was associated with a poor prognosis in
older patients. Total thyroidectomy and aggressive
postoperative 131I therapy are recommended for all
patients with pulmonary metastasis from well-dif-
ferentiated thyroid cancer, and this treatment reg-
imen provides optimal long-term survival for pa-
tients aged 40 years or younger.
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